U.S. Online Retail and Ecommerce Stock News

EQT Corporation's Board of Directors has declared a quarterly cash dividend. The dividend decision reflects the company's ongoing commitment to returning cash to shareholders. The announcement arrives as EQT (NYSE:EQT) trades around $56.13 per share. EQT, trading at about $56.13, has attracted attention with multi year returns that are very large, including a 90.5% return over 3 years and a 238.3% return over 5 years. In the shorter term, the stock shows a 9.9% return over the past 30 days...

GATX stock in focus GATX (GATX) is drawing investor attention after recent share price moves, with the stock last closing at $189.13. That price sits alongside solid trailing returns and fresh fundamental data now available. See our latest analysis for GATX. Recent momentum has been firm, with a 7.5% 1 month share price return and a 21.3% 3 month share price return, contributing to a 3 year total shareholder return of 78.3%. This suggests strengthening sentiment rather than fading...

Why Clorox (CLX) is back on many investors’ radar Clorox (CLX) has caught fresh attention after recent trading, with the stock now around $119.59 and showing positive returns over the past month and past 3 months. See our latest analysis for Clorox. Recent trading has added to that momentum, with a 30 day share price return of 12.62% and a 90 day share price return of 13.86%, even though the 1 year total shareholder return is still a 15.39% decline. This mix of shorter term strength and...

For investors wondering whether Intel at US$50.24 is still reasonably priced or if most of the easy gains are already behind it, this article walks through what the current numbers are really saying about the stock. Over the short term, Intel has returned 2.9% over the last 7 days and 10.3% over the last 30 days. Its year to date return is 27.6% and its 1-year return is 154.1%, compared to 80.3% over 3 years and a 10.6% decline over 5 years. These mixed return figures sit against a backdrop...

Why Graham Holdings (GHC) Is On Investors’ Radar Today Graham Holdings (GHC) has drawn attention after recent share price moves, with the stock closing at $1,118.60. That puts fresh focus on how its diversified operations and current return profile fit into long term portfolios. See our latest analysis for Graham Holdings. While the latest 3.42% one day share price decline and softer 7 day and 30 day share price returns may hint at cooling short term momentum, Graham Holdings still shows...

Sohu.com (SOHU) just posted its FY 2025 third quarter numbers, with revenue of US$180.2 million, basic EPS of US$0.32 and net income excluding extra items of US$8.7 million setting the tone for the latest update. The company has seen revenue move from US$151.9 million in Q3 2024 to US$180.2 million in Q3 2025, while basic EPS shifted from a loss of US$0.52 to a profit of US$0.32. This gives investors a cleaner read on how margins are shaping up after a volatile run of results. See our full...

In early February 2026, European Union competition regulators formally charged Meta Platforms with breaching antitrust rules by excluding rival artificial intelligence assistants from its WhatsApp messaging service, and signaled they may impose interim measures to prevent what they view as serious and irreparable harm to competition. The case puts WhatsApp’s Business API at the center of a broader fight over how much control a dominant messaging platform should have over access for...

Cleveland Cliffs (CLF) just posted its FY 2025 numbers with Q3 revenue of US$4.7b and a basic EPS loss of US$0.50, alongside trailing twelve month revenue of US$18.6b and a basic EPS loss of US$3.40. Over recent quarters the company has seen revenue move between US$4.3b and US$5.2b while basic EPS has ranged from a small loss of roughly US$0.00 to a loss of US$1.00 per quarter, setting a mixed backdrop for how you read this latest print. With the shares at US$12.31, investors are likely to...

In early February 2026, Pfizer reported mixed 2025 financial results, reaffirmed 2026 revenue guidance, highlighted progress in its GLP-1 obesity pipeline, secured FDA Priority Review to expand HYMPAVZI’s hemophilia indication, and joined the TrumpRx drug pricing platform with discounted access to more than 30 medicines. Together, these developments underscore how Pfizer is trying to offset patent expiries and waning COVID-19 revenues by building new specialty and obesity franchises while...

Dynatrace (DT) just posted its Q3 2026 scorecard with recent quarterly revenue running at about $493.8 million and Basic EPS of roughly $0.19, set against a trailing 12 month picture that includes Basic EPS of $1.69 and revenue of about $1.9 billion, plus earnings growth in the dataset of 210.1% over the past year. The company has seen revenue move from $399.2 million in Q1 2025 to $493.8 million in Q2 2026 and quarterly Basic EPS shift from $0.13 to $0.19 over the same period. Year long...

Waters (WAT) FY 2025 earnings snapshot Waters (WAT) reported Q3 FY 2025 revenue of US$799.9 million and basic EPS of US$2.50, with trailing 12 month EPS of US$10.91 on revenue of about US$3.1 billion. The company’s quarterly revenue rose from US$708.5 million in Q2 2024 to US$771.3 million in Q2 2025, and then to US$799.9 million in Q3 2025. Over the same periods, basic EPS moved from US$2.41 to US$2.47 and then to US$2.50, highlighting a story focused on consistent earnings and resilient...

This article examines whether Medline, at around US$47.37, is trading at fair value or something more compelling, and explores what the current price might be indicating. Over shorter time frames, the stock has returned 5.2% over the last week, 16.9% over the last 30 days and 16.6% year to date. These moves may have drawn the attention of investors who follow momentum and shifts in risk sentiment. Recent news about Medline has focused on its position in the healthcare space and how investors...

Trigger and recent performance snapshot Taiwan Semiconductor Manufacturing (NYSE:TSM) has attracted fresh attention after a period of strong share price movement, with the stock showing double digit returns over the past month and over the past 3 months. Investors considering that performance may also note annual revenue of US$3.81b and net income of US$1.72b, alongside a value score of 3 that can support basic screening approaches. See our latest analysis for Taiwan Semiconductor...

TG Therapeutics (TGTX) has been in focus after presenting new BRIUMVI data for relapsing multiple sclerosis at the ACTRIMS forum and launching a national MS awareness campaign with actress Christina Applegate. See our latest analysis for TG Therapeutics. At a share price of US$29.58, TG Therapeutics has seen recent momentum pick up, with a 1 month share price return of 3.9% following BRIUMVI data updates and the Christina Applegate MS awareness campaign. This compares with a 1 year total...

Why Brookfield Business Partners Stock Is Back on Investors’ Radar Brookfield Business Partners (NYSE:BBU) just paired its 2025 earnings release with a fresh share buyback update and an affirmed dividend plan tied to its upcoming corporate reorganization, drawing fresh attention from income focused investors. See our latest analysis for Brookfield Business Partners. The confirmed dividend, completed 1% share buyback and narrowing annual net loss have arrived alongside stronger trading...

Roblox (NYSE:RBLX) reported strong fourth quarter results, highlighting solid bookings and active user metrics. The company introduced facial age estimation and more than 145 new safety initiatives across its platform. Management emphasized a focus on leading online safety standards for both younger users and a growing adult audience. Roblox runs a global 3D social and gaming platform where users create, share, and play content built by the community. The latest safety updates sit alongside...

PVH Corp. recently announced a collaboration with OpenAI to co-create custom AI tools across Calvin Klein, Tommy Hilfiger and its broader operating model, and earlier affirmed a quarterly cash dividend of US$0.0375 per share payable on March 25, 2026 to shareholders of record on March 4, 2026. The AI partnership is designed to embed advanced analytics into product design, demand planning, inventory optimization and consumer engagement, potentially reshaping how PVH runs its core fashion and...

In early February 2026, Exact Sciences reported that its Oncotype DX Breast Recurrence Score test has now guided treatment decisions for more than two million early-stage HR+, HER2- breast cancer patients worldwide, supported by over two decades of clinical evidence and broad global adoption. The company highlighted that Oncotype DX remains the only genomic assay proven to be both prognostic and predictive for chemotherapy benefit, with published models suggesting meaningful lifetime cost...

Meritage Homes (MTH) is back in focus after its latest earnings release, which combined lower annual revenue and net income with real estate impairments, flat 2026 revenue guidance, sizable buybacks, and record community growth. See our latest analysis for Meritage Homes. At a share price of $75.91, Meritage Homes has seen stronger recent momentum, with a 7 day share price return of 8.15% and a 90 day share price return of 10.21%. Its 5 year total shareholder return of 83.21% shows how the...

Recent research coverage highlights Excelerate Energy’s history of outperforming earnings estimates, pointing to past quarterly surprises and a current positive Earnings ESP, with the next report scheduled for February 25, 2026. An interesting angle is how the combination of a positive Earnings ESP and a mid-range Zacks Rank is shaping expectations around Excelerate Energy’s ability to outpace consensus forecasts. With this backdrop of anticipated earnings outperformance, we’ll explore what...

Denali Therapeutics (DNLI) has drawn fresh attention after presenting clinical and preclinical data at the 22nd Annual WORLDSymposium, updating investors on its Enzyme Transport Vehicle programs and upcoming regulatory milestones for rare disease candidates. See our latest analysis for Denali Therapeutics. Those WORLDSymposium updates and the recent shareholder and analyst call come after a 90 day share price return of 35.13% and a 30 day share price return of 23.42%. However, the 1 year...

In early February 2026, AGCO Corporation reported fourth-quarter 2025 results with quarterly sales of US$2,920.2 million, a return to net profitability, and full-year 2025 sales of US$10,082 million alongside earnings per share from continuing operations of US$9.75. The company also issued 2026 guidance targeting net sales of US$10.4 billion to US$10.7 billion and earnings per share of about US$5.50 to US$6.00, while showcasing new Fendt and Massey Ferguson innovations such as the Fendt e100...

CNX Resources reported past fourth-quarter 2025 results showing total production volumes of 152.3 Bcfe, average daily production of 1,654.8 MMcfe, revenue of US$610.48 million, and net income of US$196.25 million, alongside increased 2026 production guidance and a larger US$4.45 billion share buyback authorization. The combination of higher volumes, a swing from loss to profit, and a very large expansion of the repurchase program highlights management’s confidence in cash generation and...

Why recent analyst moves matter for Westlake stock Mizuho’s decision to shift Westlake (WLK) from an Outperform rating to Neutral, while other firms keep buy calls in place, has put fresh attention on what current prices already reflect. See our latest analysis for Westlake. The recent analyst debate comes on the heels of strong short term momentum, with a 4.08% 1 day share price return and a 51.19% 90 day share price return, contrasting with a 1 year total shareholder return decline of...